One-Year Outcomes of a European Transcatheter Aortic Valve Implantation Cohort According to Surgical Risk
Key result
Among 1,785 patients treated with the SAPIEN 3 valve, 1-year all-cause mortality was 10.3%, 11.4%, and 17.1% in low-, intermediate-, and high-risk groups, substantially lower than predicted by logES.
Why the study?
Transcatheter aortic valve implantation is increasingly used in lower-risk surgical patients, but the distribution of surgical risk categories, their clinical outcomes, and the calibration and discrimination of logES and EuroSCORE II needed assessment.
What are the 1-year clinical outcomes and the predictive accuracy of surgical risk scores in patients with severe aortic stenosis undergoing TAVI with the SAPIEN 3 valve across different risk categories?
Population
1785 patients with severe aortic stenosis treated with the SAPIEN 3 transcatheter heart valve
Comparison
Baseline logES <10% vs 10% to 20% vs ≥20%
Design
European prospective registry
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Risk scores poorly discriminate and calibrate TAVI outcomes; leaves open need for dedicated TAVI-specific models.
Study Design
Type
Cohort (n=1,785)
Multicenter
Yes
Structured PICO
What are the 1-year clinical outcomes and the predictive accuracy of surgical risk scores in patients with severe aortic stenosis undergoing TAVI with the SAPIEN 3 valve across different risk categories?
P
Population
1,785 patients with severe aortic stenosis treated with the SAPIEN 3 transcatheter heart valve in a European prospective registry, followed for 1 year.
E
Exposure
Transcatheter aortic valve implantation (TAVI) using the commercially available SAPIEN 3 transcatheter heart valve
O
Outcome
All-cause mortality and cardiac mortality at 1 year, and the calibration and discrimination power of the logistic EuroSCORE (logES) and EuroSCORE IIhard clinical
In a real-world European registry, 1-year mortality after SAPIEN 3 TAVI was substantially lower than predicted by surgical risk scores, demonstrating poor calibration of logES and EuroSCORE II for TAVI patients.
Cite This Study
Tarantini et al. (2019) conducted a cohort in severe aortic stenosis (n=1,785). SAPIEN 3 transcatheter heart valve was evaluated on All-cause mortality at 1 year. Among 1,785 patients treated with the SAPIEN 3 valve, 1-year all-cause mortality was 10.3%, 11.4%, and 17.1% in low-, intermediate-, and high-risk groups, substantially lower than predicted by logES.